Ionone monoterpenoid compound and its preparation method and application
Through the ionone monoterpene compounds trichosanate B(1) and trichosanate C(2) isolated and prepared from Trichosanone skin, the problem of lack of effective anti-complement drugs in the prior art was solved, and effective inhibition of the complement system was achieved. , has potential clinical therapeutic value.
Patent Information
- Application Number
- CN202310163862.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-02-24
AI Technical Summary
In the prior art, ionone monoterpenes in Trichosanthes kirilowii have not been found as compounds for complement inhibition, and there is a lack of effective anti-complement drugs to treat complement-related diseases.
The ionone monoterpene compounds trichosanate B(1) and trichosanate C(2) were isolated and identified from the Trichosanone skin, and extracted by ethanol permeation, concentration under reduced pressure, suspension, extraction, silica gel column chromatography separation, and petroleum These compounds were prepared by the steps of ether-ethyl acetate gradient elution, n-hexane-ethyl acetate gradient elution, reverse phase ODS column chromatography and methanol-water gradient elution, and other steps of eluting.
The compounds trichosanate B(1) and trichosanate C(2) have strong inhibitory effects on the classical pathways of the complement system and have potential clinical value in the treatment of complement-related diseases.
Smart Images

Figure CN116217398B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of traditional Chinese medicine pharmacy, and in particular relates to an ionone monoterpene compound and a preparation method and application thereof. Background Art
[0002] The complement system is an important component of the body's innate immunity, which is composed of a variety of soluble proteins and membrane-bound proteins. It plays an important role in the body's life activities such as defense against foreign substances, inflammatory response, dissolution of immune complexes, removal of apoptotic cells, and enhancement of humoral immune response. Overactivation of the complement system is closely related to a variety of diseases such as infection, autoimmune system diseases, and tumors, such as systemic lupus erythematosus, respiratory distress syndrome, and rheumatoid arthritis. This overactivation of complement and its adverse consequences can be alleviated or avoided by inhibiting the regulation of complement activity. Therefore, it is of great clinical value and practical significance to find effective complement inhibitory active compounds to develop anti-complement drugs to treat these complement-related diseases.
[0003] Trichosanthes peel is derived from the dried mature peel of the plant Trichosanthes kirilowii Maxim. or Trichosanthes rosthornii Harms of the Cucurbitaceae family. It is mainly used clinically to treat cough with phlegm and heat, chest tightness and flank pain. Existing pharmacological studies have shown that Trichosanthes peel has multiple pharmacological effects such as anti-inflammatory, antibacterial, antiviral, improving the cardiovascular system, and anti-oxidation. Phytochemical studies have shown that it mainly includes terpenes, sterols, flavonoids, alkaloids, organic acids and fatty acids and their ester compounds.
[0004] In recent years, there have been many studies on the chemical composition and biological activity of Trichosanthes peel extracts, but so far there has been no report on the use of Trichosanthes peel, especially the ionone monoterpenoid compounds therein, as complement inhibitory compounds. Summary of the invention
[0005] The purpose of the present invention is to provide a novel compound with anti-complement activity, which relates to an ionone monoterpene compound separated and identified from the peel of Trichosanthes kirilowii.
[0006] A further object of the present invention is to provide the use of the above-mentioned ionone monoterpene compounds in the preparation of anti-complement drugs.
[0007] The purpose of the present invention can be achieved by the following technical solutions:
[0008] One of the technical solutions of the present invention is to provide an ionone monoterpene compound, wherein the ionone monoterpene compound has the following general structural formula: in,
[0009] When R is dodecyl, the compound is trichosanate B(1),
[0010] When R is tetradecyl, the compound is trichosanate C(2).
[0011] The second technical solution of the present invention is to provide a method for preparing ionone monoterpene compounds as described in the first technical solution, comprising the following steps: taking Trichosanthes kirilowii peel, and sequentially subjecting it to ethanol percolation extraction, reduced pressure concentration, suspension, and extraction, subjecting the obtained extract to silica gel column chromatography, and eluting it with a petroleum ether-ethyl acetate gradient, after each obtained fraction is detected by thin layer chromatography, the target fraction is again separated by silica gel column chromatography, and eluted with a n-hexane-ethyl acetate gradient, after each obtained fraction is detected by thin layer chromatography, the target fraction is separated by reversed phase ODS column chromatography, and eluted with a methanol-water gradient, after each obtained component is detected by high performance liquid chromatography, the target component is purified by semi-preparative liquid phase, and isocratically eluted with methanol-water to obtain compound trichosanate B (1) and compound trichosanate C (2).
[0012] Furthermore, the peel of Trichosanthes kirilowii was extracted by 95% ethanol by volume.
[0013] Furthermore, the gradient of petroleum ether-ethyl acetate is a volume ratio from 1:0 to 0:1.
[0014] Furthermore, the gradient of n-hexane-ethyl acetate was from 100:0 to 1:10 in volume ratio.
[0015] Furthermore, the gradient of methanol-water was from 70:30 to 100:0 by volume.
[0016] Further, compound trichosanate B (1) was obtained under isocratic elution with a methanol-water volume ratio of 95:5.
[0017] Further, compound trichosanate C (2) was obtained under isocratic elution with a methanol-water volume ratio of 97:3.
[0018] The third technical solution of the present invention is to provide the use of the ionone monoterpene compound as described in the first technical solution, wherein the ionone monoterpene compound is used for preparing an anti-complement drug.
[0019] Furthermore, the anti-complement drug is a drug that has an inhibitory effect on the classical pathway of the complement system.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] The invention discloses a method for separating two ionone monoterpenoid compounds trichosanate B (1) and trichosanate C (2) from the ripe dried pericarp of the Cucurbitaceae plant Trichosanthes kirilowii by an activity-oriented separation method. The in vitro anti-complement activity test shows that the compounds trichosanate B (1) and trichosanate C (2) both have a strong inhibitory effect on the classical pathway of the complement system and can be further used for preparing anti-complement drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The figure is a flow chart for the extraction and separation of ionone monoterpenoid compounds trichosanate B (1) and trichosanate C (2) from the peel of Trichosanthes kirilowii. DETAILED DESCRIPTION
[0023] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0024] In the following examples and comparative examples, unless otherwise specified, raw materials or processing techniques are conventional commercially available raw materials or conventional processing techniques in the art.
[0025] Example 1: Preparation of ionone monoterpenoid compounds
[0026] Separation process such as Figure 1 As shown:
[0027] 31.0 kg of Trichosanthes peel was taken, mechanically crushed, and extracted by percolation with 95% (v / v) ethanol. The extract was concentrated under reduced pressure, and the extract was suspended in water after concentration, and extracted with petroleum ether, ethyl acetate, n-butanol, and water, respectively, to obtain 611 g of petroleum ether extract of the active part. 600 g of petroleum ether extract was separated by silica gel column chromatography, and gradient eluted with petroleum ether-ethyl acetate (volume ratio from 1:0 to 0:1). After thin layer chromatography detection, 5 fractions A1-A5 were obtained. The A2 fraction was analyzed by thin layer chromatography, and then separated by silica gel column chromatography, and gradient eluted with n-hexane-ethyl acetate (volume ratio from 100:0 to 1:10). After thin layer chromatography detection, 12 fractions A2A-A2L were obtained. The A2F fraction was analyzed by TLC and then separated by reversed phase ODS column chromatography, with gradient elution using methanol-water (volume ratio from 70:30 to 100:0). After TLC detection, the 12 components A2F1-A2F12 were obtained. Component A2F7 was analyzed by HPLC and then purified by semi-preparative liquid phase, with isocratic elution using methanol-water (volume ratio of 95:5) as the mobile phase to obtain compound trichosanate B (1). Component A2F8 was analyzed by HPLC and then purified by semi-preparative liquid phase, with isocratic elution using methanol-water (volume ratio of 97:3) as the mobile phase to obtain compound trichosanate C (2). The chemical structures of trichosanate B (1) and trichosanate C (2) were determined by NMR.
[0028] Compound trichosanate B (1): colorless oil; molecular formula: C 25 H 42 O3; relative molecular weight: 390; 1 H NMR (400MHz, CD3OD), δ: 6.68 (1H, dd, J = 15.8, 9.9 Hz, H-7), 6.12 (1H, d, J = 15.8 Hz, H-8), 5.59 (1H, m, H -4),5.33(1H,m,H-3),2.58(1H,d,J=9.8Hz,H-6),2.29(2H,t,J=7.3Hz,H-2'),2.27(3H,s,H-10),1.9 0(1H,dd,J=14.4,6.1Hz,H-2a),1.67(3H,s,H-13),1.61(2H,m,H-3'),1.49(1H,dd,J=14.4,6.1Hz,H -2b),1.30(16H,m,H-4'–H-11'),1.06(3H,s,H-12),0.93(3H,s,H-11),0.90(3H,t,J=7.0Hz,H-12');13 CNMR(100MHz,CD3OD)δ:200.8(C-9),175.2(C-1'),148.9(C-7),139.5(C- 5),134.3(C-8),122.3(C-4),69.3(C-3),55.5(C-6),39.5(C-2),35.5(C-2 '),33.9(C-1),33.1(C-10'),30.1–30.8(C-4'–C-9'),29.1(C-12),27.1( C-10),26.6(C-11),26.1(C-3'),23.7(C-11'),22.9(C-13),14.4(C-12').
[0029] Compound trichosanate C(2): colorless oil; molecular formula: C 27 H 46 O3; relative molecular weight: 418; 1 H NMR (400MHz, CD3OD), δ: 6.68 (1H, dd, J = 15.8, 9.9 Hz, H-7), 6.12 (1H, d, J = 15.8 Hz, H-8), 5.59 (1H, m, H -4),5.32(1H,m,H-3),2.58(1H,d,J=9.9Hz,H-6),2.29(2H,t,J=7.3Hz,H-2'),2.27(3H,s,H-10),1.9 0(1H,dd,J=14.4,6.0Hz,H-2a),1.67(3H,s,H-13),1.61(2H,m,H-3'),1.49(1H,dd,J=14.4,6.0Hz,H -2b),1.29(20H,m,H-4'–H-13'),1.06(3H,s,H-12),0.93(3H,s,H-11),0.88(3H,t,J=7.0Hz,H-14'); 13 CNMR(100MHz,CD3OD)δ:200.8(C-9),175.2(C-1'),148.9(C-7),139.5(C- 5),134.3(C-8),122.3(C-4),69.3(C-3),55.5(C-6),39.5(C-2),35.5(C-2 '),33.9(C-1),33.1(C-12'),30.1–30.8(C-4'–C-11'),29.1(C-12),27.1( C-10),26.6(C-11),26.1(C-3'),23.7(C-13'),22.9(C-13),14.4(C-14').
[0030] Example 2: In vitro anti-complement classical pathway assay
[0031] Take 0.1mL of complement prepared with guinea pig serum, add barbiturate buffer (BBS) to prepare a solution with a volume ratio of 1:10, and then dilute it with BBS to make solutions with volume ratios of 1:20, 1:40, 1:80, 1:160, 1:320, 1:640 and 1:1280. Take 0.1mL of 1:1000 hemolysin, the above-mentioned complements and 2% sheep red blood cells (SRBC) and dissolve them in 0.3mL BBS, mix well, place in a 37℃ water bath for 30min, and then put into a low-temperature high-speed centrifuge, centrifuge at 5000rpm and 4℃ for 10min. Take 0.2mL of the supernatant from each tube and put it in a 96-well plate, and measure its absorbance at 405nm. The experiment also set up a full hemolysis group (0.1mL 2% SRBC dissolved in 0.5mL distilled water). The absorbance of the distilled water-dissolved blood vessel is used as the full hemolysis standard to calculate the hemolysis rate. Plot the graph with complement dilution as the X-axis and hemolysis percentage as the Y-axis. Select the lowest complement concentration that achieves a similar high hemolysis rate as the critical complement concentration required to ensure that the system can hemolyze normally. Take the critical concentration of complement and mix it with the test sample of different concentrations, add appropriate amount of BBS, hemolysin and 2% SRBC, put it in a low-temperature high-speed centrifuge after 30 minutes in a 37°C water bath, centrifuge it at 5000rpm and 4°C for 10 minutes, take 0.2mL of the supernatant from each tube and put it in a 96-well plate, and measure the absorbance at 405nm. The experiment also set up a test sample control group, a complement group and a full hemolysis group. The hemolysis rate is calculated by deducting the absorbance value of the test sample control group from the absorbance value of the test sample. Plot the graph with the test sample concentration as the X-axis and the hemolysis inhibition rate as the Y-axis, and calculate the concentration of the test sample required to inhibit hemolysis by 50% (CH 50 ), the results are shown in Table 1. Both trichosanate B (1) and trichosanate C (2) have inhibitory effects on the classical pathway of the complement system.
[0032] Table 1 Inhibitory effects of compounds 1 and 2 on the classical pathway of the complement system (Mean±SD, n=3)
[0033]
[0034] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.
Claims
1. An ionone monoterpene compound, characterized in that: The ionone monoterpene compound has the following general structural formula: in, When R is dodecyl, the compound is trichosanate B (1); When R is tetradecyl, the compound is trichosanate C(2).
2. A method for preparing an ionone monoterpene compound as claimed in claim 1, characterized in that: The steps include: Take the peel of Trichosanthes kirilowii and extract it by filtration with 95% ethanol by volume, concentrate it under reduced pressure, suspend it and extract it with petroleum ether in sequence. The obtained petroleum ether extract is separated by silica gel column chromatography and eluted with petroleum ether-ethyl acetate gradient in a volume ratio of 1:0 to 0:
1. After the obtained fractions are detected by thin layer chromatography, the target fraction is separated by silica gel column chromatography again and eluted with n-hexane-ethyl acetate gradient in a volume ratio of 100:0 to 1:
10. After the obtained fractions are detected by thin layer chromatography, the target fraction is separated by reversed phase ODS column chromatography and eluted with methanol-water gradient in a volume ratio of 70:30 to 100:
0. After the obtained components are detected by high performance liquid chromatography, the target component is purified by semi-preparative liquid phase and eluted isocratically with methanol-water to obtain compound trichosanate B (1) and compound trichosanate C (2).
3. The method for preparing ionone monoterpene compounds according to claim 2, characterized in that: Compound trichosanate B (1) was obtained under isocratic elution with a methanol-water volume ratio of 95:
5.
4. The method for preparing ionone monoterpene compounds according to claim 2, characterized in that: Compound trichosanate C (2) was obtained under isocratic elution with a methanol-water volume ratio of 97:
3.
5. A use of the ionone monoterpene compound as claimed in claim 1, characterized in that: The ionone monoterpene compound is used for preparing anti-complement drugs.
6. The use of ionone monoterpene compounds according to claim 5, characterized in that: The anti-complement drug is a drug that has an inhibitory effect on the classical pathway of the complement system.
